Gilead Safety Narrative Is Spreading, But Direction Never Resolved - Classic Edge-Decay Profile
The Opportunity
Upstream flags a Gilead-linked safety narrative in rare disease and orphan drugs, but routes it to propagation_monitor because the edge is decaying and the direction is MIXED. That is the key point: the system sees the topic travelling, but it does not see a clean economic mechanism that consistently points to up or down. In that state, the only honest stance is AVOID, because a mixed-direction, spreading narrative is where you get chopped by headline drift.
The Timing
This is explicitly a catalytic propagation posture with low trade confidence (33) and high crosswind risk in the broader market (42). Market regime is Bearish 72, but the regime does not help if the sign of the mechanism is not resolved. What would convert this into something tradable is hard anchoring to a specific product and adverse event category, plus a regulator or dataset-based artefact that clearly shifts expected liability, utilisation, or label risk in one direction.
The Evidence
No hydrated_evidence bundle is provided upstream for this specific row in the 7A payload excerpt, and freshness is not populated, which is consistent with a propagation-monitor item where the story exists but the incremental edge is closing. The actionable evidence gap is therefore not a nuance - it is the product: without primary artefacts and a resolved sign, you are trading noise.